- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00798239
Pilot Study to Assess Safety/Prelimary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery
March 7, 2012 updated by: BioSurface Engineering Technologies, Inc
A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness Of Prefix Compared To Iliac Crest Bone In Subjects With DDD Undergoing Transforaminal Lumbar Interbody Fusion
This is a pilot study to evaulate the safety and prelimary effectiveness of Prefix as compared to autogenous bone for spinal fusion procedures in skeletally mature subjects with degenerative disc disease (DDD) at one level from L2-S1.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Confidential
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
- Confidential
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- Confidential
-
Toronto, Ontario, Canada, M4N 3M5
- Confidential
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- Confidential
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented diagnosis of DDD requiring single level fusion (L2-S1) with up to Grade I Spondylolisthesis
- Have a preoperative screening qualifying VAS and ODI scores
- Be a skeletally mature male or a non-pregnant, non-lactating female, age 18 -70 inclusive
- Have not been sufficiently responsive to at least 6 months of non-operative treatment prior to study enrollment
Exclusion Criteria:
- Are female subjects who are pregnant or nursing, or women planning to become pregnant during the first year (12 months) following the surgery
- A history of previous surgery in the lumbar spine with or without attempted fusion
- Grade II or greater spondylolisthesis
- More than 0 degrees of kyphosis at the operated disc space
- Evidence of scoliosis in the lumbar region of more than 10 degrees
- Collapsed disc space with bridging osteophytes
- A systemic or local infection at the site of surgery
- An acute fracture of the spine at the time of enrollment in the study
- An active history of systemic malignancy
- A medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study
- A known hypersensitivity to any of the components of the product or a known titanium allergy or a known allergy to polyetheretherketone (PEEK)
- A history of any autoimmune disease, such as, systemic lupus erythematosus, Addison's disease, Crohn's disease, or rheumatoid arthritis
- A history of any severe allergy or anaphylaxis, or a history of hypersensitivity to protein pharmaceuticals, or have had any previous exposure to a protein pharmaceutical
- Are receiving treatment (before or during surgery) with a drug (e.g., steroids, methotrexate, etc.) that interferes with bone metabolism or are being treated with a bone growth stimulator
- A medical condition requiring radiation, chemotherapy or immunosuppression, or a medical condition requiring systemic corticosteroids
- Are covered under workmen's compensation insurance or prisoners
- Are transient or have been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an in-subject substance abuse program
- Have participated in clinical studies within 3 months of enrollment
- Have a body mass index (BMI) greater than 35
- Use tobacco products (also includes, e.g. nicotine patch or nicotine gum), or have smoked cigarettes within 6 weeks preceding enrollment
- Known to require additional surgery to the lumbar spinal region within the next 6 months
- Have symptomatic multilevel degenerative disease requiring possible instrumented fusion of more than one vertebral level
- Have previously been treated with, or exposed to, therapeutic levels of Bone Morphogenetic Proteins (BMPs), i.e., synthetic or recombinant
- Have a documented medical history or radiographic evidence of a metabolic bone disease (e.g., osteoporosis or osteopenia) or other condition which would negatively impact the bone healing process (e.g. history of Paget's disease, osteomalacia, or other osteodystrophy) or preclude the subject from receiving pedicle screw fixation
- Are involved in or planning to engage in litigation related to back and/or leg pain
- Require chronic SQ or IV heparin therapies
- Have an Osteoporosis Risk Assessment Instrument (ORAI) score > to 9 points and, if so, will require a qualifying DEXA scan T score
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
The control arm is Iliac Crest Autograft
|
autograft
|
Experimental: Prefix 150
Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
|
150 micorgrams/cc BVF
Other Names:
750 micrograms/cc BVF
Other Names:
|
Experimental: Prefix 750
Prefix (AMPLEX) B2A Enhanced Ceramic Granules
|
150 micorgrams/cc BVF
Other Names:
750 micrograms/cc BVF
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Removal/revision or supplemental fixation of the graft material requiring reoperation at the index level, Safety (adverse events), Fusion "success" based on X-rays, Change from baseline in neurological exam scores and ODI scores
Time Frame: 12 months post surgery
|
12 months post surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Volume of blood loss/transfused blood during surgery, Blinded independent assessment of fusion by CT and other radiographic assessments, Change from baseline in pain scores using VAS and change from baseline in SF-36 v2™ total and subscale scores
Time Frame: 12 months post surgery
|
12 months post surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Brent Atkinson, PhD, BioSurface Engineering Technologies, Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Anticipated)
May 1, 2012
Study Completion (Anticipated)
July 1, 2012
Study Registration Dates
First Submitted
November 24, 2008
First Submitted That Met QC Criteria
November 25, 2008
First Posted (Estimate)
November 26, 2008
Study Record Updates
Last Update Posted (Estimate)
March 9, 2012
Last Update Submitted That Met QC Criteria
March 7, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PFX-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
Clinical Trials on Iliac crest autograft
-
Tehran University of Medical SciencesCompletedGenovarumIran, Islamic Republic of
-
Technical University of MunichCompletedFracture, Healed, Fibrous Union
-
Indonesia UniversityUnknownHealing of FractureIndonesia
-
NuVasiveCompleted
-
Ross LeightonCanadian Orthopaedic Trauma SocietyWithdrawnNon Union Diaphyseal FracturesCanada
-
BioSurface Engineering Technologies, IncUnknownDegenerative Disc Disease | SpondylolisthesisUnited States
-
Medtronic Spinal and BiologicsTerminatedLumbar Spine DegenerationUnited States
-
Universidad Autonoma de Nuevo LeonCompletedPseudoarthrosisMexico
-
Shahid Beheshti University of Medical SciencesCompletedCleft of Alveolar RidgeIran, Islamic Republic of
-
OrthoCarolina Research Institute, Inc.Stryker Trauma GmbHWithdrawnAdult Acquired FlatfootUnited States